Meeting
2019 ASCO Annual Meeting
Survival outcomes in glioma patients with noncanonical IDH mutations: Beyond diagnostic improvements.
Authors
Enrico Franceschi
Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Institute of Neurological Sciences, Bologna, Italy
Enrico Franceschi , Dario De Biase , Annalisa Pession , Alicia Tosoni , Alexandro Paccapelo , Michela Visani , Giovanni Tallini , Chiara Maria Argento , Benedetta Urbini , Stefania Bartolini , Alba Ariela Brandes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2028)
DOI
10.1200/JCO.2019.37.15_suppl.2028
Abstract #
2028
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comprehensive gene expression analysis of IDH1/2 mutant biliary cancers (BC).
First Author: Francesca Battaglin
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas
Poster
2023 ASCO Annual Meeting
Methylation-based prediction of myelodysplastic syndrome survival outcomes.
First Author: Alvin Shi
Poster
2022 ASCO Annual Meeting
Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma.
First Author: Kristina Fanucci